On October 13, Professor Shi Yuan Yuan, Chairman and General Manager of Shenzhen Cell Valley, Dr. Xiang Hua, Deputy General Manager and Director, Dr. Fu Yu Chen, Assistant to the Chairman, Tang Hui, Business Director of Shenzhen-Hong Kong Cell Valley, and Sun Rui, Head of the Marketing Department, visited Guangzhou Royal Lee Cancer Hospital for an exchange and discussion. They were warmly received by Mr. Li Min, Chairman of Thailand Royal Lee International Group and Guangzhou Royal Lee Cancer Hospital, a renowned patriotic Thai-Chinese entrepreneur, Luo Ai Ming, Supervisor of the Hospital Group, Li Li, Deputy General Manager and Director, Ma Lan Ying, Chief Medical Officer, Dr. Xiang Tong, Head of the Anti-Tumor Immune Cell Research Project, and Li Jia Long, President of Guangdong Cunjin Education Group, among others. Through thematic discussions, both parties clarified the direction of collaboration, officially opening a new chapter in the clinical application of cell therapy technologies and the coordinated development of international services.

Accompanied by Chief Medical Officer Ma Lan Ying and heads of relevant departments, the Shenzhen Cell Valley team toured key areas such as the Medical Imaging Center, International Medical Center, Multidisciplinary Collaborative Diagnosis and Treatment Center, and VIP Ward Zone. They highly praised Guangzhou Royal Lee Cancer Hospital's advanced medical facilities, international service system, and high-level clinical capabilities. Both parties agreed that the hospital possesses exceptional conditions for advancing the clinical translation of biomedical technologies and serving international patients, laying a solid foundation for future in-depth collaboration.

During the subsequent symposium, the two sides engaged in in-depth discussions on collaboration directions and reached multiple consensuses. For international patient services, leveraging Guangzhou Royal Lee Cancer Hospital's established international patient referral network and service experience, combined with Shenzhen Cell Valley's strengths in high-quality cell product R&D and GMP-level production, they will jointly establish an "International Patient Cell Therapy Service Pathway," providing overseas patients with comprehensive, one-stop precision medical solutions that include cell therapy.

Regarding collaboration in specific medical fields, both parties have identified four key focus areas: anti-aging, chronic disease management, comprehensive health maintenance, and adjunctive cancer therapy. Leveraging Shenzhen Cell Valley's core cell products as the technological foundation, customized application plans will be developed based on clinical needs. Additionally, the meeting established a cooperation plan to "jointly build an in-hospital cell preparation center," aiming to achieve closed-loop management of cell product preparation, testing, and clinical application through standardized systems, thereby enhancing both product safety and operational efficiency.

Chairman Li Min presented a gift to Chairman Shi YuanYuan

This strategic partnership fully leverages the strengths of both parties: Guangzhou RoyalLee Cancer Hospital's domestic and international medical resources and global service capabilities will precisely address patients' clinical needs, while Shenzhen Cell Valley's innovative cell technologies and product systems will provide robust technical support for diagnosis and treatment. Both parties stated that this collaboration will not only diversify the hospital's treatment methods and enhance its international medical competitiveness but also establish a high-quality platform for the clinical translation and market expansion of Shenzhen Cell Valley's cell products. Moving forward, the two parties will jointly promote the standardized application of cell technology in clinical settings, facilitate the deep integration of comprehensive health industries and international medical services, and deliver safer, more efficient, and innovative cell therapy solutions to patients worldwide.

Introduction to Guangzhou RoyalLee Cancer Hospital and Thailand RoyalLee International Group

Located in Guangzhou's Sino-Singapore Knowledge City, Guangzhou RoyalLee Cancer Hospital is a JCI-accredited tertiary specialized hospital built to international standards. Dedicated to comprehensive cancer prevention, treatment, and rehabilitation, the hospital spans approximately 30,000 square meters, featuring nearly 400 patient beds and multiple internationally standardized laminar flow operating rooms, equipped with advanced imaging devices and smart information systems. With its well-established international medical service system and exceptional patient experience, the hospital is establishing itself as a leading cancer diagnosis, treatment, and rehabilitation center in South China and beyond.

Its parent company, RoyalLee International Group of Thailand, is a multinational enterprise group focused on high-end healthcare, wellness, hospitality, and international investments, headquartered in Bangkok, Thailand. The group upholds the philosophy of "internationalization and premium services," with healthcare and wellness projects across multiple s in Asia. Chairman Li Min, a renowned overseas Chinese leader and entrepreneur, also serves as Chairman of the Board of Thailand Central Chinese Television and President of the Thailand-China Charity Work Committee. He has been honored with awards such as the Fifth "Top Ten Chinese Economic Talents" Public Welfare Award and "Top Ten Economic Figures of the Year in South China." For years, he has been dedicated to promoting exchanges and cooperation between China and Thailand in healthcare, culture, and education.